Basit öğe kaydını göster

dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorDemirci, Umut
dc.contributor.authorBuğdaycı, Fatma
dc.contributor.authorTural, Deniz
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorPaydaş, Semra
dc.contributor.authorYılmaz, Coşkun
dc.contributor.authorTuna, Hande
dc.contributor.authorSezer, Ahmet
dc.contributor.authorYeşil Çinkir, Havva
dc.contributor.authorErman, Münire
dc.contributor.authorEralp, Yeşim
dc.contributor.authorÇabuk, Devrim
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.contributor.authorDemirkazık, Ahmet
dc.contributor.authorKaraoğlu, Aziz
dc.contributor.authorYazılıtaş, Doğan
dc.contributor.authorÇay Şenler, Filiz
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.authorCoşkun, Hatice
dc.contributor.authorYıldız, İbrahim
dc.contributor.authorÖztop, İlhan
dc.contributor.authorBeypınar, İsmail
dc.contributor.authorAydın, Kübra
dc.contributor.authorKaplan, M.
dc.contributor.authorMeydan, Nezih
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorSeber, Samile
dc.contributor.authorArslan, Çağatay
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorÇiçin, İrfan
dc.date.accessioned2019-12-25T07:56:49Z
dc.date.available2019-12-25T07:56:49Z
dc.date.issued2019en_US
dc.identifier.citationKılıçkap, S., Demirci, U., Buğdaycı, F., Tural, D., Korkmaz, T., Paydaş, S. ... Çiçin, İ. (2019). Lorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkey. Journal of Thoracic Oncology içinde (S558-S559. ss.). Elsevier Science. https://doi.org/10.1016/j.jtho.2019.08.1166en_US
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.urihttps://doi.org/10.1016/j.jtho.2019.08.1166
dc.identifier.urihttps://hdl.handle.net/20.500.12511/4670
dc.description.abstractBackground: Lorlatinib, a third generation ALK and ROS1 inhibitor, is indicated for the treatment of patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one second-generation ALK inhibitor. The aim of this study is to evaluate the efficacy and safety of lorlatinib in an Expanded Access Program (EAP) in Turkey. Method: The EAP was open-label, multicenter, and single-arm. Patients were eligible to receive lorlatinib (100 mg po/day) if they had advanced stage ALK-or ROS1-positive NSCLC and had progressed on crizotinib and/or second generation ALK inhibitors such as ceritinib or alectinib. The primary endpoint was PFS with lorlatinib. Secondary endpoints were objective response rate, overall survival, and safety.en_US
dc.language.isoengen_US
dc.publisherElsevier Scienceen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectALK Positiveen_US
dc.subjectROS1 Positiveen_US
dc.subjectLorlatiniben_US
dc.subjectAdvanced Stage Lung Canceren_US
dc.titleLorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkeyen_US
dc.typeconferenceObjecten_US
dc.relation.ispartofJournal of Thoracic Oncologyen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume14en_US
dc.identifier.issue10en_US
dc.identifier.startpageS558en_US
dc.identifier.endpageS559en_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1016/j.jtho.2019.08.1166en_US
dc.identifier.wosqualityQ1en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster